The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 5.21 — safe zoneOK
- Earnings quality 71/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Aurinia Pharmaceuticals Inc. reports it. History and quarterly detail are in the app.
- Net product sales$271.3M
- License, collaboration and royalty revenue$11.7M
- Service Revenue$11.7M
Leadership changes
From Aurinia Pharmaceuticals Inc.'s own filings, the day they're filed.
- Ryan Cole · Chief Operating Officer · appointmenteff. 2026-03-23
- Michael Hearne · Chief Financial Officer · appointmenteff. 2026-03-23
- Kevin Tang · Chief Executive Officer · appointmenteff. 2026-03-23
Latest filings
- 8-K · Company announcement2026-06-04
- 8-K · Company announcement2026-05-11
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-07
- DEF 14A · Annual proxy (pay & governance)2026-04-21
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Aurinia Pharmaceuticals Inc., every answer cited🔒
- The Intelligence Brief — added when Aurinia Pharmaceuticals Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.